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ABSTRACT
Introduction Vagus nerve stimulation (VNS) is a
neuromodulation therapy that can reduce the seizure
burden of children with medically intractable epilepsy.
Despite the widespread use of VNS to treat epilepsy, there
are currently no means to preoperatively identify patients
who will benefit from treatment. The objective of the
present study is to determine clinical and neural network-
based correlates of treatment outcome to better identify
candidates for VNS therapy.
Methods and analysis In this multi-institutional
North American study, children undergoing VNS and
their caregivers will be prospectively recruited. All
patients will have documentation of clinical history,
physical and neurological examination and video
electroencephalography as part of the standard clinical
workup for VNS. Neuroimaging data including resting-
state functional MRI, diffusion-tensor imaging and
magnetoencephalography will be collected before
surgery. MR-based measures will also be repeated 12
months after implantation. Outcomes of VNS, including
seizure control and health-related quality of life of both
patient and primary caregiver, will be prospectively
measured up to 2 years postoperatively. All data will be
collected electronically using Research Electronic Data
Capture.
Ethics and dissemination This study was approved
by the Hospital for Sick Children Research Ethics Board
(REB number 1000061744). All participants, or substitute
decision-makers, will provide informed consent prior to
be enrolled in the study. Institutional Research Ethics
Board approval will be obtained from each additional
participating site prior to inclusion. This study is funded
through a Canadian Institutes of Health Research grant
(PJT-159561) and an investigator-initiated funding grant
from LivaNova USA (Houston, TX; FF01803B IIR).

Strengths and limitations of this study
► This study will enrol up to 500 patients to assess

the long-term outcomes of vagus nerve stimulation
(VNS) therapy on seizure frequency, seizure severity
and quality of life in children with epilepsy with data
collection up to 2 years postoperatively.
► This study will build a working collaboration among
leading paediatric epilepsy treatment centres across
North America performing VNS in children with
epilepsy.
► This study will develop a machine learning predictive model to identify patients who may benefit most
from VNS based on clinical phenotypes and differences in structural and functional brain connectivity.
► A potential limitation of this study is loss to follow-up
due to the lengthy 2-year follow-up period resulting
in missing or incomplete data.

INTRODUCTION
Epilepsy is the most common serious neurological condition of childhood.1 Approximately
one-third of children continue to have debilitating seizures and are diagnosed with drug-
resistant epilepsy after failure of optimised
two or more antiepileptic drugs over 2 years.2
This cohort of patients with medically intractable epilepsy is disproportionately affected
by the medical and psychosocial burden of the
illness3 and consumes 80% of epilepsy-related
healthcare expenses.4 5 Furthermore, uncontrolled seizures are known to interfere with
typical childhood development,6 culminating
in disability and challenges with schooling.
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To mitigate the burden of epilepsy, surgical interventions are increasingly emphasised, with resective surgery
demonstrating the best long-term outcomes.3 7 8 In those
children who are not candidates for resective surgery, or
those who continue to have debilitating seizures postoperatively, neuromodulation strategies may be considered.
Vagus nerve stimulation (VNS) is a form of neuromodulation whereby an electrical stimulus is delivered to the
vagus nerve at the level of the neck through an implanted
pulse generator resulting in the modulation of cortical
excitability.9 VNS has been shown to reduce seizure
frequency in children with intractable epilepsy leading to
improvements in quality of life, arrest of cognitive decline
and improved mood and behaviour.10–12
The individual patient response to VNS is highly variable and unpredictable. A meta-analysis of randomised
controlled trials of VNS encompassing 439 adults and
children demonstrated considerable heterogeneity in
outcomes, with fewer than half of implanted patients
achieving significant seizure reduction.13 Furthermore, in
paediatric populations, seizure response rates following
VNS may be as low as 25%,12 suggesting that a significant
number of patients accept surgical risk with a low likelihood of seizure-freedom. The lack of objective markers
to preoperatively identify good VNS candidates subjects
some children to an unnecessary invasive surgical procedure and, in resource-limited health systems, deprives
others who would be more likely to benefit. As a result,
there is an unmet need to identify preoperative predictive markers that can identify and stratify patients who will
benefit from VNS.
A recent review identified biomarkers of VNS responsiveness in patients with drug-resistant epilepsy.14 Notably,
differences in intrinsic brain network connectivity were
found to be a highly promising biomarker in identifying
patients likely to benefit from VNS. The therapeutic effect
of VNS is thought to be mediated by afferent projections
of the vagus nerve via brainstem pathways to the thalamus
and cortex, which serves to modulate cortical excitability,
rendering the brain less susceptible to seizures.15 16 Collectively, this system is termed the vagus afferent network
(VagAN).17 Measures of structural and functional brain
network connectivity within the VagAN have been previously studied to investigate the variability in patient
responsiveness to VNS therapy.18–20 Such connectomic
studies leverage advanced imaging and neurophysiological tools to study neural architecture by statistically
mapping fibres and shared patterns of neuronal activity
linking different brain regions.21
The proposed study will build on previous findings
through a multi-institutional, prospective observational
design. VNS outcomes will be measured in terms of
seizure control and health-related quality of life (HRQoL)
of both the child and their primary caregiver up to 2 years
post implantation. Resting-state functional MRI (rs-fMRI),
diffusion tensor imaging (DTI) and magnetoencephalography (MEG) will be used to investigate how structural and functional brain connectivity within the VagAN
2

differs among patients who demonstrate good and poor
response to VNS, relative to a historical normative age-
matched and sex-matched cohort. Somatosensory evoked
fields (SEFs) during MEG will be used to study associations between afferent brainstem pathways and seizure
response to VNS. Last, we will leverage recent advances
in the imaging of brain connectomics in combination
with machine learning to characterise and predict VNS
responsiveness in intractable epilepsy. It is anticipated
that this work may aid in identifying paediatric patients
with intractable epilepsy who are most likely to benefit
from VNS.
STUDY OBJECTIVES AND DESIGN
The primary goal of this study is to collect longitudinal,
multicentre data to identify the ideal surgical candidate
for VNS. This study will build a collaboration between
leading epilepsy centres across North America with technology, expertise and experience in VNS therapy. Each
reported and
centre will contribute clinical, parent-
patient-reported outcomes and multimodal imaging data
to the study over a period of 4 years.
The specific objectives of the study are:
To assess the long-term outcomes of VNS in children with
intractable epilepsy
Seizure control will be compared between baseline and
prespecified postoperative time points (6 months, 12
months and 24 months) using standardised measures.
Changes in HRQoL of both the child and primary caregiver will be measured using a series of parent-reported
and child-reported measures. Effects of VNS therapy on
health-resource utilisation (HRU) will also be explored.
To identify clinical and imaging predictors of seizure outcome
for VNS
We will study the association between the preimplantation structural and functional connectome in patients
and their seizure response to VNS strategies. Individual
indices of VNS outcome will be compared against neuroimaging data.
To develop a predictive model to identify patients who may
benefit from VNS
By combining structural and functional imaging connectomics of the VagAN into a machine learning algorithm,
a predictive model to identify response to VNS will be
developed and made freely accessible. The predictive
model may enable better prediction of which patients
are likely to benefit from VNS and assist with clinical
decision-making.
METHODS AND ANALYSIS
Study environment
The study will be led by the Hospital for Sick Children
(SickKids), Toronto, Ontario, Canada. Thirteen additional institutions across North America will participate,
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Figure 1 Organisational structure of the study. Participating clinicians enter data directly into the Research Electronic Data
Capture (REDCap) online database at baseline, 6 months, 12 months and 24 months. Parent-reported and child-reported
measures are completed through secure REDCap links at the same time points. Neuroimaging is completed at baseline and 12
months postoperatively. CarerQoL, The Care-related Quality of Life Instrument; CHU9D, Child Health Utility; GAD-7, Generalised
Anxiety Disorder Scale; HRU, health resource utilisation; ILAE, The International League Against Epilepsy seizure classification;
KIDSCREEN, KIDSREEN generic health-related quality of life measure; McHugh, The McHugh classification of seizure freedom;
MEG, magnetoencephalography; QOLCE, The Quality of Life in Childhood Epilepsy Questionnaire; QIDS, The Quick Inventory of
Depressive Symptomatology; SSQ, The Seizure Severity Questionnaire; VNS, vagus nerve stimulation.

including CHU Sainte-Justine in Montreal, Arkansas Children’s Hospital, University of Pittsburgh Medical Center,
University of Utah, University of Indiana, Washington
University, University of Alabama, Seattle Children’s
Hospital, Children’s Hospital of Wisconsin, Nicklaus Children’s Hospital in Miami, University of British Columbia,
Baylor College of Medicine in Texas and University of
California, Los Angeles. Independently, each of the
collaborating centres are leaders in the comprehensive
evaluation and surgical treatment of epilepsy. All institutions have access to a 3T MRI scanner with experience in
imaging children with epilepsy. In addition, a subset of
these sites have expertise in and access to MEG research.
Organisational structure and governance
All data will be collected and managed using Research
Electronic Data Capture (REDCap; V.9.5.3) tools, hosted
on secure servers at SickKids.22 23 REDCap is a web-based
software platform designed to support data capture for
research studies. Clinical data will be directly entered into
the online REDCap database by the investigating physicians at baseline, 6 months, 12 months and 24 months
post implantation. Child-reported and parent-reported
information will also be directly entered into the database through secure, unique email links at the same time
points. The organisation structure of the study is shown
in figure 1.
All study data will be deidentified using unique study
codes for each site. Each site will be responsible for maintaining their own participants’ personal health information on a master list. Only the lead site (SickKids) will have
access to the deidentified data from all sites. The study
Siegel L, et al. BMJ Open 2022;12:e055886. doi:10.1136/bmjopen-2021-055886

team at SickKids will oversee access and data security,
appropriate follow-up and communications with external
sites. The scientific advisory committee responsible for
making decisions for sharing data and providing input
regarding data analysis, data interpretation and research
publications will comprise of the SickKids study team as
well as the PIs at the external sites. The SickKids principle investigator (PI) is responsible for all data collected
for the study and the deidentified clinical imaging data
collected from all sites as part of the study.
Eligibility criteria
Children aged 0–18 years who will be undergoing VNS
for the treatment of medically intractable epilepsy will
be included in the study for clinical data collection and
parent-
reported and child-
reported scales where able.
Children 6 years and older will additionally be invited to
complete preoperative and postoperative neuroimaging.
The decision to pursue VNS therapy will be made locally
at each site, in part influenced by the surgeon and/or
patient/family preference; this study does not play any
role in the decision-
making of treating patients with
VNS. Children who have had previous resective epilepsy
surgery and subsequent VNS will also be included.
Ability to read and understand English and/or French
is not mandatory for all participants. Completion of the
questionnaires is optional and dependent on the participant and parent’s ability to understand English or use
language interpretation services provided by the hospital.
We estimate that each year approximately 50 children
will undergo VNS at SickKids, and we will recruit 200
patient–parent pairs globally (approximately 20 patients
3
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from each site). This sample size is sufficient to adjust for
clinical heterogeneity of subjects and to test a predictive
model in an independent cohort. A sample size calculation with a conservative effect size of 0.4, desired power of
0.8 and significance of 0.05 would require only 52 patients
for a paired analysis of seizure frequency before and after
VNS. However, given the number of institutions involved,
expectation of a complicated hierarchical mixed-effects
model, and the high likelihood of missing data across
multiple institutions, we believe that 200 patient–parent
pairs is a parsimonious target to produce accurate and
reliable analyses.
Recruitment
Patients scheduled to undergo VNS will be identified
by the clinical team at their respective institution, who
will inform the patients and families about the study.
Further information about the study will be provided
to the patients and families inviting their participation.
The study research coordinator will contact the families
within a few days to answer any questions. For those who
wish to participate, the research coordinator will obtain
informed consent from both the child and their parent/
legal guardian. For children who do not have capacity to
consent for themselves, consent will be sought by their
substitute decision-maker and assent will be sought from
the child.
All patients will undergo a history, physical and neurological examination, video electroencephalography, and
occasionally, neuropsychological testing as part of the
clinical workup for VNS and epilepsy surgery, which is
the standard practice at all participating sites. Relevant
clinical data will be collected from patient charts for all
participants (table 1).
Outcomes
The primary outcome of interest is change in clinical
seizure control after VNS implantation. Secondary
outcomes include differences in intrinsic structural and
functional connectivity within the VagAN, changes in
brain connectivity over time, HRQoL of both the child and

primary caregiver and HRU. All clinical seizure control
and VNS stimulation settings will be measured at baseline,
6 months, 12 months and 24 months post implantation.
This study will not enforce a no-drug-change window to
mimic realistic clinic practice and understand the effect
of VNS for patients with medically refractory epilepsy. If
available, neuropsychologic test data are collected prior
to surgery and a year after VNS implantation, depending
on individual site resources and clinical indications.
Specific measures used are described below.
Clinical seizure control
Seizure control will be assessed using the following scales:
i. International
League
Against
Epilepsy (ILAE)
classification.24
ii. The McHugh classification.25
iii. The Seizure Severity Questionnaire (SSQ),26 a caregiver-
reported review of aspects of seizures before, during
and after seizures, with responses related to the individual’s most common type of seizure.
VNS stimulation settings
Stimulation settings of the patient’s current parameters
will be recorded prior to adjustment or changes.
i. Percentage of time and autostimulation function.
ii. Current (mA) normal mode, current (mA) autostimulation and current (mA) of the magnet.
iii. Heart rate sensitivity and heart rate threshold.
iv. System resistance.
Health-related quality of life
We will measure changes in HRQoL of the child and caregiver using the following instruments:
The Quality of Life in Childhood Epilepsy Questionnaire (QOLCE)
The Quality of Life in Childhood Epilepsy Questionnaire,27–29 a parent-rated epilepsy-specific instrument
that covers five domains: physical, social, emotional
well-being, cognition and behaviour. Items are rated
on a 5-point Likert scale, with the time referent being
the previous 4 weeks.

►

Table 1 Clinical data collected in Research Electronic Data Capture
Form

Data fields

Clinical background

Age at VNS procedure, sex, age at seizure onset, handedness, IQ before VNS insertion, genetic
mutations, comorbid conditions, family history of seizures, presence of infantile spasm, number
and type of antiepileptic drugs (AEDs), seizure classification, frequency and aetiology, video EEG
localisation, normal versus abnormal neuroimaging results, location of lesion, previous surgeries,
date of VNS procedure, VNS model
 Seizure frequency and severity, seizure classification, number and type of AEDs, HRQoL, HRU,
adverse events,
 VNS settings:
 Percentage of time and autostimulation function, current (mA) normal mode, current (mA)
autostimulation, current (mA) magnet, heart rate sensitivity, heart rate threshold and system
resistance

Follow-up (6 months, 12
months, 24 months after
VNS implantation)

EEG, electroencephalography; HRQoL, health-related quality of life; HRU, health resource utilisation; IQ, intelligence quotient; VNS, vagus
nerve stimulation.

4
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The KIDSCREEN-27, a dual child-
rated and parent-
rated generic instrument30 31 that measures five dimenbeing, psychological well-
being,
sions: physical well-
autonomy and parents, social support and peers and
school environment. This scale has been validated
for the ages of 8–18 years in children with a variety of
chronic illness and developmental disorders.32–37
► The Child Health Utility (CHU9D), a child-rated generic
instrument that measures nine dimensions: worry,
sadness, pain, tiredness, annoyance, school, sleep,
daily routine and activities. The CHU9D has been validated in children aged 7–17 years.38–42
We will ask parents to complete questionnaires on their
own depressive and anxiety symptoms and quality of life
using the following measures:
43
► The Quick Inventory of Depressive Symptomatology.
44
► The Generalised Anxiety Disorder Scale.
45
► The Care-related Quality of Life Instrument, a measure of
the impact of providing informal care on caregivers in
terms of subjective burden and happiness.
►

Health resource utilisation
HRU is a parent-reported measure which includes: (1)
physician visits (family physician, paediatrician, neurologist, psychiatrist and other specialists); (2) emergency
department visits; and (3) number of hospitalisations
and number of days hospitalised. We will also measure
caregivers’ productivity days lost related to their child’s
health.
Neuroimaging
Timing
Neuroimaging measures will be collected at baseline and
12 months postoperatively (MR-
based measures only).
Patients who are ineligible for neuroimaging without
sedation may still be enrolled for collection of clinical and neuropsychological data without the imaging
component.
MRI
At SickKids, MR imaging will be acquired on our research
scanner, a Siemens Prisma 3T using the 20-ch head and
neck matrix coil. Imaging at participating sites will be
performed on MRI scanners with similar capabilities and
imaging protocols will be matched as closely as possible.
Preimplantation, the following images will be acquired:
1. Five minutes eyes-open resting state BOLD fMRI, during
which participants will be instructed to passively view
a centrally presented fixation cross (repetition time
(TR): 1500 ms, echo time (TE): 30 ms, fractional anisotropy (FA): 70°, field of view (FOV): 222×222×150
mm, 3.0 mm isotropic voxels).
2. Sagittal T1-weighted 3D Magnetization Prepared - Rapid
Gradient Echo (MPRAGE) images (TR: 1870 ms, TE:
3.14 ms, FA: 9°, FOV: 240×256×192 mm, 0.8 mm isotropic voxels).
3. Sagittal T2-weighted images (TR: 3200 ms, TE: 408 ms,
FOV: 263×350×350 mm, 0.8 mm isotropic voxels).
Siegel L, et al. BMJ Open 2022;12:e055886. doi:10.1136/bmjopen-2021-055886

4. Multishell DTI (TR: 3800 ms, TE: 73 ms, FOV:
244×244×140 mm, 2.0 mm isotropic voxels) at gradient strengths of b=1000 s∙mm−2 with 36 directions;
b=1600 s∙mm−2 with 46 directions; b=2600 s∙mm−2 with
67 directions.
For images acquired at the 12-
month follow-
up, we
have adapted the above sequences for compatibility with
the MR-conditional VNS stimulator. Additionally, these
images will be acquired at 3T with a head transmit/
receive coil, which is available at all participating institutions acquiring these images.
1. Axial T1-weighted 3D images (TR: 1640 ms, TE: 2.3 ms,
FA: 8°, FOV: 263×350×350 mm, 0.5 mm isotropic voxels, 2D distortion corrected, iPAT off).
2. Single-shell diffusion weighted imaging (TR: 13 700 ms, TE:
92 ms, FOV: 220×220×144 mm, 3.4×3.4×3.0 mm voxels,
30 direction, b=1000 s∙mm−2).
3. Seven minutes eyes-
open resting state BOLD fMRI (TR:
2530 ms, TE: 30 ms, FA: 90°, FOV: 220×220×144 mm,
2.7×2.7×4.0 mm voxels).
During anatomical and DTI scans, participants are
invited to view their choice of movie through the available MRI video systems at each institution, typically MRI-
compatible goggles.
The MR session will take approximately 1 hour. In
our experience, this amount of time is sufficient for the
children to become acclimatised and settled, run all the
sequences and allow for repetition due to movement if
necessary. Structural scans will be pushed to the clinical
Picture Archiving and Communication System (PACS)
and read by a neuroradiologist. Incidental findings will
be shared with the family. Given our extensive experience
in paediatric imaging, we do not anticipate any technical
challenges in data collection.
Magnetoencephalography
MEG data will be recorded at 2400 Hz with an online
600 Hz antialiasing low-
pass filter using a 151-
channel
CTF system (CTF MEG International Service, Coquitlam,
British Columbia, Canada) within a magnetically shielded
room and processed off-line. MEG recording will take half
an hour, with breaks as needed. MEG data will be acquired
with continuous head localisation allowing us to reject
data with excessive head motion.46 47 Resting state MEG
will be acquired while participants are positioned supine
for 5 min with eyes open focusing on a fixation cross
and for 10 min viewing the Inscapes video; a non-social,
non-verbal movie paradigm consisting of slowly moving
abstract shapes with a gentle piano score48 49 produced
with the goal of increasing compliance in children while
maintaining the resting state as much as possible.
Somatosensory evoked fields (SEFs)
SEFs will be acquired during a median nerve stimulation paradigm (electrical stimulation, constant current
square wave, 0.2 ms duration, 4 Hz, 400 trials, supramotor
threshold, median nerve at the wrist, left arm).5 We have
previously successfully applied this method to detect
5
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somatosensory responses in children with epilepsy.50 The
afferent pathways that produce the SEF are closely related
to the ascending brainstem circuits of theVagAN,51 52
which also project to the primary somatosensory cortex.51
SEF is therefore ideal to study associations between
afferent brainstem pathways and seizure response to VNS.
Data analysis
Treatment outcomes
To assess the outcomes of VNS, we will evaluate the baseline characteristics and outcomes at each follow-up on all
parent-reported and child-reported measures. For each
participant, there will be frequency measurements of the
main (most disabling) and the total (all types) of seizures.
This will inform the relationship between VNS and the
quality of life of children and their caregivers. We will use
absolute change in seizure outcome (McHugh Scale) at
2 years post implantation as the dependent variable in a
repeated measures analysis of variance. The independent
variables will include age, age at seizure onset, number
of antiseizure drugs, ILAE classification, normal versus
abnormal MRI, type and location of lesion (if applicable).
Bi-variable regression will be used to identify variables for
inclusion into multivariable linear regression analysis,
and those with p<0.2 will be included in the multivariable
regression. A subgroup analysis will be performed for
children with resective surgery.
Structural and functional imaging analysis
Imaging correlates of outcome will be evaluated using
a hierarchical linear mixed effects model including
age and seizure outcomes as explanatory variables to
be regressed against neuroimaging data. Analysis of
the neuroimaging data will consist of (1) measures of
microstructure (fractional anisotropy), (2) inter-regional
structural connectivity (on the basis of streamline fibre-
tracking), (3) measures of functional connectivity (bold
correlations in fMRI, envelope amplitude correlations
in MEG, bandlimited phase synchrony in MEG) and (4)
evoked fields in MEG. The proposed work will additionally profile the connectome of VNS responders and non-
responders patients to develop a predictive model and
identify the relevant circuitry mediating the therapeutic
effect of treatment. Responders to VNS will be defined
as those who experience 50% or greater reduction in
seizure frequency after VNS, as is consistent with the literature.18 Greater granularity will result from collection of
outcomes such as the SSQ and HRQoL, which can be
directly compared with seizure response and neuroimaging data.
Our previous neuroimaging studies in this population have revealed the following correlates to VNS
responsiveness: (1) VNS responders exhibit enhanced
preoperative connectivity of the thalami to the anterior
cingulate cortex and left insula compared with non-
responders on rs-
fMRI18; (2) responders have higher
fractional anisotropy values in left-sided thalamocortical,
limbic and hemispheric association fibres compared with
6

non-responders on DTI19; (3) responders demonstrate
significantly greater functional connectivity in a network
encompassing left thalamic, insular and temporal nodes
on preoperative MEG19; and (4) responders show significantly greater functional connectivity in limbic and sensorimotor brain networks in response to median nerve
stimulation on SEFs recorded during MEG.20 These
findings were supported using a support vector machine
(SVM) learning algorithm trained to classify response to
VNS based on this connectivity, with responders correctly
classified with 86% and 89.5% accuracy.18 19
Predictive machine learning model development
Using multidimensional data, we will develop, publish
and share with the research community a prediction
model for presurgical identification of children undergoing VNS. An appropriate machine learning model will
be selected and trained using inputs (structural and functional connectivity and SEF properties and connectivity)
and known responses (McHugh class) to find the best
classification scheme to categorise patients as responders
responders. We will use supervised machine
or non-
learning algorithms, during which is a labelled training
dataset is used first to train the underlying algorithm,
then applied to an unlabeled test dataset to categorise
them into similar groups. Accepted outcome measures
applicable to a range of machine learning models will
be used to measure how well the model can distinguish
between the two cohorts (responders vs non-responders).
Different supervised machine learning models will be
tested to identify the method to provide the best predictive power; a non-comprehensive list of model options
include logistic, random forest, decision tree, SVM,
XGBooster, neural network. Not only will this tool stand
to benefit patients who may undergo VNS for medically
refractory epilepsy, it will also provide a robust framework
for characterising neural connectivity and applying this
knowledge to primary neurological conditions, amenable
to surgery.
Patient and public involvement
Patients and their families were not involved in the design
of the original protocol. The dissemination of the study
results will involve patients, families and the public as data
are planned to be presented at epilepsy awareness events.

ETHICS AND DISSEMINATION
This study was approved by the Hospital for Sick Children Research Ethics Board (REB number 1000061744).
This study has also been approved by the Saint Justine
University Hospital Center REB, Nicklaus Children’s
Research Institute Office for Human Research Protection
Program, Mattel Children’s Hospital and David Geffen
School of Medicine at the University of California Los
Angeles Institutional Review Board (IRB), University
of Alabama IRB for Human Use, Arkansas Children’s
Hospital IRB, IRB Nicklaus Children’s Research Institute
Siegel L, et al. BMJ Open 2022;12:e055886. doi:10.1136/bmjopen-2021-055886

BMJ Open: first published as 10.1136/bmjopen-2021-055886 on 8 April 2022. Downloaded from http://bmjopen.bmj.com/ on April 25, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

Office for Human Research Protection Program, University of Pittsburgh IRB, Seattle Children’s Hospital IRB, the
University of British Columbia/Children’s and Women’s
Health Centre of British Columbia REB, University of
Utah IRB, the Washington University in St. Louis IRB,
the Children’s Hospital of Wisconsin IRB and the Baylor
College of Medicine IRB. Participants, or substitute
decision-makers, will provide informed consent prior to
be enrolled in the study. Any incidental findings will be
shared with a physician within the patient’s circle of care
for disclosure and appropriate follow-up. This study will
allow us to assess the effectiveness of VNS in children with
intractable epilepsy in a detailed and methodical manner.
By identifying the factors that will predict good seizure
outcome, we will be able to better predict patients who
will benefit most from VNS and assist with appropriate
patient selection on the basis of clinical and radiographic
predictors. VNS is associated with significant capital and
consumable costs related to the procedure. In addition
to avoiding unnecessary surgeries in patients who are
unlikely to benefit from therapy, improved patient selection will result in better allocation of healthcare resources
and provide more access to VNS therapies for patients
who may not be currently considered candidates. This
work will also serve as a framework for applying connectomics to other neurological diseases as a novel approach
for optimising patient care.
It is imperative to identify potential challenges to
research productivity and methods to mitigate such
potential obstacles. We anticipate challenges related
to the multicentre nature of the study; imaging in the
paediatric population; and confounding effects of clinical heterogeneity, including antiepileptic drugs. In
relation to the multicentre nature of the study, we have
standardised data collection across the centres. Quality
assessment and control is performed on all neuroimaging
datasets collected from the multisite collaboration. We
will also apply multilevel random-effects statistics, which
theoretically accounts for differences among centres.
We have had success validating and integrating neuroimaging data from multiple centres using this approach.6 It
should be emphasised that some degree of variability is
welcome, as we wish to test the predictive model using
data from the different centres in order to generalise its
utility. Second, imaging in the paediatric population is
associated with important challenges. All participating
centres have exceptional and unique experience in the
imaging of children. Our techniques of preimaging counselling and rehearsal have been successful in collecting
imaging data on hundreds of school age children in
special populations, including children with intractable
epilepsy. Third, there will be unavoidable heterogeneity
in clinical factors within each child studied, for instance
the medications that are administered. We will collect an
extensive database of clinical, electrophysiological and
imaging variables to test whether any confounding factor
is contributing to heterogeneity in VNS responsiveness or
differences in connectomics. Importantly, our hypotheses
Siegel L, et al. BMJ Open 2022;12:e055886. doi:10.1136/bmjopen-2021-055886

are grounded in the underlying neurobiology of the VNS
circuitry; the common VagAN is thought to mediate treatment effect.53 Because of these a priori considerations,
we have previously performed connectomics studies in
comparable patient cohorts successfully.5
We anticipate that integrated knowledge translation
will include a final predictive model derived from this
research, which will be freely available for download on
a supported online platform for clinicians and scientists
worldwide to improve patient selection for VNS in children with medically intractable epilepsy.
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